Compare Invesco S&P 500 Momentum ETF (SPMO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Momentum ETF vs Tango Therapeutics Inc. — how do they compare? Invesco S&P 500 Momentum ETF trades at $143.71 (market cap $23.04B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 6.1× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 2,008,654). Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Momentum ETF for 55 Days and Tango Therapeutics Inc. for 0 Days on average.
| SPMO | TNGX | |
|---|---|---|
Market Cap | $23.04B | $3.75B |
Volume | 2,008,654 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $32.90 |
52-Week Low | $107.84 | $7.50 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPMO, the Invesco S&P 500 Momentum ETF, trades at $148.03, down 0.89% on the day amid a bearish technical signal. The ETF recently completed its semi-annual reconstitution, adding 54 stocks including Apple and Merck while removing Nvidia. Its momentum strategy has historically outperformed the S&P 500 but faces near-term volatility from concentrated sector exposure.
Outlook remains mixed with strong long-term momentum performance offset by current technical weakness. Investment opportunity lies in capturing S&P 500's fastest-rising stocks, though risks include high volatility and sector concentration. The ETF's structural edge suggests potential for continued outperformance despite recent underperformance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
